We can’t show the full text here under this license.
Abstract
SGLT2 inhibitors have consistently and significantly reduced cardiovascular events, albuminuria, and glomerular filtration rate in patients with diabetic kidney disease.
- Diabetic kidney disease is increasingly common as a complication of diabetes.
- Traditional therapies have limited effectiveness in slowing progression to end-stage kidney disease.
- SGLT2 inhibitors have transformed the treatment landscape for diabetic kidney disease and associated conditions.
- GLP-1 receptor agonists show potential to slow renal disease progression and reduce albuminuria, despite fewer studies specifically on kidney disease.
- Further research is needed to identify which patients will benefit most from these novel therapies.
Simplified